Antibody fragment shows promise in myasthenia gravis

Autoantibodies bond to receptor (achr) blocking the acetylcholine transmitters in Myasthenia gravis (MG).

argenx shared trial and real-world data on Vyvgart (efgartigimod alfa) in patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive at the European Academy of Neurology (EAN) Annual Meeting.

In gMG, Vyvgart demonstrated consistent and repeatable improvements across patient subtypes, a favourable and predictable safety profile, and the ability to individualise treatment across both intravenous (IV) and subcutaneous (SC) administration and dosing schedules.

The company also presented data from Vyvgart in chronic inflammatory demyelinating polyneuropathy (CIDP) and empasiprubart, a first-in-class C2 inhibitor, in multifocal motor neuropathy (MMN).

Results from the ADHERE and ADHERE+ clinical trials of Vyvgart SC in CIDP show 67% of patients demonstrated evidence of clinical improvement (ECI).

Patients treated with Vyvgart SC maintained a clinical response to treatment and remained relapse-free longer than those treated with placebo.

The Phase II ARDA Study for empasiprubart (ARGX-117) demonstrated a 91% reduction in the need for IVIg rescue compared to placebo.

Vyvgart is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies.

It was the first approved FcRn blocker in the United States, EU and China for the treatment of adults with gMG who are AChR antibody positive and in Japan for the treatment of adults with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

It is also approved for IV use in adults with primary immune thrombocytopenia (ITP) in Japan.

Luc Truyen, Chief Medical Officer at argenx, said: “We are excited to share our advancements in gMG and CIDP as well as initial positive findings in MMN at EAN.  The collective data set demonstrate that we are discovering new ways to transform autoimmunity.”

Janssen-Cilag also reported positive results from its Phase III Vivacity-MG3 study assessing its nipocalimab therapy for the treatment of patients with generalised myasthenia gravis (gMG) at the EAN.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free